unravelling the genetics of complex diseases can be enhanced by focusing on underlying risk factors. For example, studies of lipoproteins and blood pressure have shown that these factors correlate well with the risk of vascular disease 1, 2 . Insights into the pathogenesis of breast cancer may be informed in a similar way using mammographic density (MD) because both may be determined by similar genetic variants. In fact, the number of genetic and environmental factors influencing an intermediate such as MD is likely to be smaller than that influencing the endpoint, namely breast cancer 3 . Consequently, studies to identify genes for MD could be more powerful and efficient than those for breast cancer.
MD reflects the proportion of stromal and epithelial tissue relative to fat on a mammogram. Dense breast tissue appears light or lucent on radiographs of breast images; by contrast, fat appears dark. early measures of MD were qualitative, relying on visual scales of morphological features 4, 5 . Contemporary methods seek to provide a quantitative and continuous measure of the amount of dense tissue in the mammographic breast image [6] [7] [8] [9] 
. Results from both measures show that MD is strongly
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Abstract | Mammographic density (MD) reflects variations in fat, stromal and epithelial tissues that are thought to be regulated by several genes. High MD is an established risk factor for breast cancer; therefore, genes that regulate MD may indirectly influence breast cancer. These genes might also be fewer in number and easier to identify than those for breast cancer risk outside of inherited predisposition syndromes. in this Perspective, we review the limited genetic studies of MD and propose future directions. associated with breast cancer risk 10 . Indeed, the ~30% 11 of women who have dense breast tissue in >50% of the total breast area have a 3-5-fold increased risk of breast cancer compared with women with no measurably dense breast tissue 10, 11 . Although the inclusion of MD in breast cancer risk prediction models has minimally improved their overall discrimination among women of recommended mammogram screening age [12] [13] [14] , the identification of genes that regulate MD might further enhance the ability to identify women at risk of developing breast cancer. Improved risk prediction will be particularly important for young women not yet of mammogram age, for whom prevention efforts will be most beneficial.
Evidence for a genetic influence evidence for a genetic influence on MD has come from studies on family history, familial aggregation, twin and segregation analyses. with a family history of breast cancer are more likely to have a high MD, as assessed by Wolfe pattern
, than women without such a history. Both positive [15] [16] [17] and negative [18] [19] [20] results were found. More recently, two large studies of 35, 019 (ReF. 21) and 6,146 (ReF. 22) women from populationbased mammography registries have illustrated positive associations between family history of breast cancer and higher MD as determined by Breast Imaging-Reporting and Data System (BI-RADS; BOX 1) 21, 22 . The odds of a woman having dense breast tissue is 17% greater for a first-degree relative with a family history of breast cancer and 22% greater for women with breast cancer that was diagnosed at <50 years of age 21 .
Familial aggregation and twin studies. Data on related individuals, although based on small sample sizes, show similar mammographic patterns among mother-daughter and sister pairs compared with unrelated pairs 23 . Familial correlation of per-cent MD was estimated to be 22% among 275 sister pairs but attenuated to 16% after adjustment for body weight.
Twin studies demonstrated greater concordance of Wolfe patterns among monozygotic compared with dizygotic twin pairs 24, 25 . A large multicentred study of 571 monozygotic and 380 dizygotic twin pairs estimated that 60-67% of the variation in MD is attributable to common genetic factors 26, 27 . estimates of heritability have been stronger when twin pairs have similar body mass index (BMI) (77% versus 28% when dissimilar on BMI) 28 . This underscores the importance of accounting for BMI and possibly other covariates when searching for genetic influences on MD.
Segregation analysis. The above analyses implicate a genetic influence on MD but not the possible mode of transmission of a putative gene(s) (Mendelian pattern of inheritance, for example). In the only reported segregation analysis, the distribution of MD among 1,370 females in 258 independent families was compatible with Mendelian dominant or co-dominant transmission of a major gene. This was only apparent after adjustment for covariates, including BMI and postmenopausal hormone (PMH) use 29 . under the dominant model, 12% of the female population could carry an allele for higher MD, and women carrying at least one dominant allele would have a mean MD that is 27% higher than the rest of the female population 29 .
the remainder largely evaluated candidate polymorphisms with putative functional effects that were previously examined with breast cancer. Five studies (19%) had fewer than 300 women [33] [34] [35] [36] [37] , 16 (61%) had 300-650 women 31, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] 55 and five (19%) had 1,100-2,000 women 30, 32, [52] [53] [54] . All studies except four investigations of BRCA1 and BRCA2 mutation carriers [33] [34] [35] [36] and one cross-sectional study 53 estimated MD using the computer-assisted thresholding method
Most studies adjusted statistically for age and BMI, and also adjusted or stratified by menopausal status 30, 31, 38, 39, [41] [42] [43] [44] [45] [46] [47] [48] 50, 55 or PMH use 31, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] 55 or restricted analyses to women who did 37, 52 or did not 47, 53 take PMH or to women who were premenopausal 32, 54 . Although stratification produces homogeneous subsets of women to examine associations between genetic factors and MD, the resulting sample sizes can be too small to produce any meaningful conclusions. The populations also varied and included women from screening mammogram populations who were [42] [43] [44] or were not 45, 46, 54 selected for extreme MD phenotypes, control subjects in case-control studies of breast cancer 30, 31, 41, 55 , healthy women participating in cohort studies 32, 47, 48, 52, 53 , breast cancer cases with pre-diagnosis mammograms 39, 40, 51 and a twin study 50 . The highly selected sample from a cardiovascular-focused clinical trial 37 is not discussed in the remainder of this Perspective.
Below, we focus our discussion on those polymorphisms evaluated in more than one study of per-cent MD with similar sample characteristics, and we seek to explain similar or disparate findings. The differences in absolute dense and non-dense area in relation to the polymorphisms will not be discussed.
The search for MD genes Two approaches have been used to identify genes that influence MD: a hypothesisdependent approach, in which knowledge of breast biology guides the selection of candidate genes, and a hypothesis-free approach, in which markers positioned across the genome are evaluated with MD using linkage or genome-wide association methodology.
Candidate gene analysis. This approach estimates the extent to which polymorphisms in a biologically plausible candidate gene influence MD, usually in unrelated individuals. However, our limited understanding of the biology of MD makes selection of candidate genes challenging. Furthermore, MD is a dynamic trait, decreasing with older age and menopause, and even varying transiently during the menstrual cycle. Higher densities are observed among women who are premenopausal, nulliparous, of low BMI or taking combination PMH, and lower densities among those who are postmenopausal, multiparous, of high BMI or on tamoxifen therapy. Because of these hormonal influences the majority of candidate gene studies have focused on evaluation of the pathways that regulate steroid hormone synthesis and metabolism, hormone receptors and proliferative pathways including the insulin-like growth factor (IGF) pathway FIG. 1) . However, some studies have focused on genes previously noted to be strongly (BRCA1 and BRCA2) or hypothetically (XPD (also known as ERCC2), XRCC3, and ERBB2) associated with breast cancer risk. The results from all of these candidate gene association studies are reviewed in Supplementary information S1 (table) and some are highlighted below. It should be noted that the size of these studies vary greatly, as do the aims of the studies, the characteristics of the women analysed and the method of assessing MD, which makes interpretation challenging.
Characteristics of studies. The majority of studies compared a difference in MD among women with one or two copies of a polymorphism to women with zero copies and also estimated tests for trend of a dose-response of zero, one or two copies. Of 26 identified publications (TABLe 1) , three studies examined several polymorphisms representing genetic variation throughout the entire gene and used haplotype approaches for analyses [30] [31] [32] and
Box 1 | Breast density classification methods

Qualitative methods
Wolfe pattern
4
. Visual assessment of the relative percentage of fat (appears dark) and epithelial and stromal (appears light) tissue obtained from mammographic X-rays. Four categorical patterns of breast density are described: N1 -'normal', almost completely fatty breast; P1 -mainly fatty breast with prominent ducts, up to 25% density; P2 -prominent ducts, more than 25% density; and DY -no visible ducts, diffuse and extensive nodular density. 
BI-RADS.
Quantitative methods
Planimeter (outlining tool)
6 . An acetate overlay is placed over a radiographic image of the breast to outline the breast and to trace dysplastic elements. The total breast and dense areas are measured with an outlining tool. Agreement (κ) between Wolfe score and planimeter is 0.91. Results can be reported as per-cent density distribution by quartiles or quintiles.
Boyd six-category scale 7, 93 . Radiologist assessment of the relative percentage of fat and epithelial and stromal tissue is obtained from mammographic X-rays. Individual scores for a given density estimate are assigned the midpoint of six potential categories of breast density: 0%; 5% for 0-10%; 17.5% for 10-25%; 37.5% for 25-50%; 62.5% for 50-75%; and 87.5% for 75-100%.
Computer-assisted threshold method
94
. Mammographic films are digitized (see figure) and two different threshold values selected: one separates the image of the breast from background (red line) and the other identifies the edges of the regions representing radiographically dense tissue (green line). Percent density is the proportion of total breast area calculated from the histogram of pixel values in the two different threshold areas. Results can be reported as mean per-cent density by genotype. CYP17A1 +27T>C. This polymorphism is located in the cytochrome P450 17A1 (CYP17A1) promoter region but its effect on steroid hormone biosynthesis is inconclusive 56 (FIG. 2) . Inappreciable differences in per-cent MD across genotypes were observed in four studies restricted to 94 -268 premenopausal women regardless of age (<50 years versus >50 years), study design (mammograms from prospectively enrolled healthy women versus pre-diagnosis mammograms from breast cancer cases) and ethnicity 39, 41, 42, 46 . Non-significant associations were also observed among samples of 171-1,260 postmenopausal women irrespective of current 39, 41 or past or no 39, 53 PMH use. The data, therefore, provide little support for a role of this polymorphism in MD or in breast cancer 57 .
COMT Val158Met. Catechol-Omethyltransferase (COMT) inactivates the bioactive 2-hydroxycatechol and 4-hydroxycatechol oestrogens by methylation 58 (FIG. 2) .
The valine to methionine val158Met polymorphism decreases enzyme activity 58 and is the most widely studied polymorphism in relation to MD. Among healthy premenopausal women 41, 42, 46 , carriers of two copies of the Met allele had higher MD in one study of Caucasians participating in a case-control study of breast cancer 41 , and lower MD in two studies of women enrolled from a screening mammography clinic 42, 46 . The mammography clinic studies comprised mixed ethnicities including Asians and, although adjustment was made for ethnicity, this and the younger age distribution compared with the case-control study by Haiman et al. 41 may account for the differences among relatively healthy premenopausal women. The remaining studies of COMT val158Met among premenopausal women (which included patients with breast cancer whose screening mammograms were retrieved within the 5 years preceding diagnosis 39 or whose mammograms were performed after breast cancer diagnosis but before treatment 38 ) showed only minor differences in MD across COMT genotypes, and the study by Takata et al. 38 did not evaluate healthy controls separately from cases by menopausal status.
Two studies that enrolled 67 (ReF. 39 ) and 1,260 (ReF. 53) postmenopausal women who had never used PMH or had used PMH in the past showed no particular pattern of per-cent MD across COMT genotypes. Investigations of postmenopausal women that did not differentiate among hormonal regimens but did adjust for PMH use reported either no significant differences of MD across COMT genotypes 42, 50 or significantly lower MD among carriers of both Met alleles 41 . The two studies 41, 53 closest in comparability owing to similar age distributions and study populations (healthy women participating in a nested case-control or prospective cohort study) had disparate findings, which could be due to the threefold difference in sample sizes, the statistical adjustment for PMH use 41 versus sample restriction to past or no PMH use 53 , or the method of mammogram assessments (computer-assisted 39, 41 versus visual assessment by three radiologists using the Boyd six-category scale 53 
). Statistical adjustment for PMH use or menopausal status without evaluation of the assumption that the effect is constant across strata of these variables results in pooled estimates that can conceal important stratum-specific effects. Also, although both MD assessment methods are shown to predict risk of breast cancer 10 , classification of MD using the Boyd six-category scale can overestimate risk of breast cancer among women aged >50 years compared with the computer-assisted threshold assessment method 7 . Thus, an ideal comparison of results by genotype necessarily relies on similar methodology. In summary, although the COMT val158Met polymorphism does not appear to be a strong risk factor for breast cancer 59 regardless of menopausal status 57 , the data suggest that it might influence premenopausal MD.
ESR1 XbaI and PvuII. Oestrogen receptor α (eSR1) is a nuclear receptor that mediates oestrogen or other steroid hormone action by regulating gene transcription (FIG. 2) . The two polymorphisms in intron 1 of ESR1 (known as XbaI and PvuII) have no known functional effect on gene expression 57, 60 , although intronic polymorphisms may affect the post-transcriptional processing of gene products and receptor binding affinity.
Three studies examined the XbaI polymorphism. The european Prospective Investigation into Cancer and Nutrition (ePIC) cohorts analysed cross-sectional estimates of MD across XbaI genotypes from 620 postmenopausal women in the Netherlands (ePIC-Prospect) who had never used PMH 47 and 1,286 postmenopausal women in the uK (ePIC-Norfolk) who were past or never users of PMH 53 . Whereas the ePIC-Prospect study 47 reported a significantly higher MD with increasing copies of the x variant allele, the ePIC-Norfolk study 53 reported no appreciable difference in per-cent MD across genotypes. The greater sample size in the ePIC-Norfolk study 53 is a strength,
Box 2 | polymorphisms in the iGF1 axis
Components of the insulin-like growth factor (IGF) axis may influence the tissue composition of the breast (FIG. 1) . High levels of circulating IGF1, or higher IGF1 in relation to IGF binding protein 3 (IGFBP3), correlate with higher premenopausal mammographic density (MD) 47, [87] [88] [89] [90] , similarly to their association with breast cancer risk 95 . Six studies reported on associations of 29 polymorphisms in IGF1 and 16 polymorphisms in IGFBP3 or IGFBP1 that were associated with MD. Most polymorphisms were examined in only one study and are described in Supplementary information S1 (table) . In addition to the three single-nucleotide polymorphisms discussed in the text, five polymorphisms have each been evaluated by two investigative teams. These associations of the individual polymorphisms and haplotypes with density are described below and are too few to interpret definitively. Further, associations with breast cancer risk have not been found for selected polymorphisms and haplotypes 70, 71, 96 . IGF1 polymorphisms. Four polymorphisms (rs2946834 G>A, rs7965399 T>C, rs1019731 C>A and rs1549593 G>T) have either been evaluated among ~700 premenopausal women 32, 54 or among 204 premenopausal and 917 postmenopausal women combined 30 . Of these, rs2946834 G>A in the 3′ UTR was inversely related to per-cent density among premenopausal and postmenopausal women combined who carry both copies of the A allele 30 , but not among premenopausal women only 32 . Different sample compositions make interpretation difficult. Polymorphisms rs7965399 T>C, rs1019731 C>A and rs1549593 G>T were each evaluated in premenopausal women and in premenopausal and postmenopausal women combined, with no significant differences observed in density across genotypes 30, 32, 54 . IGFBP3 rs3110697C>T. This polymorphism was investigated in two studies, one among 741 premenopausal women 54 and another among 204 premenopausal and 917 postmenopausal women evaluated separately and combined 30 . Neither showed appreciable differences in density across genotypes.
IGF1 and IGFBP3 haplotypes. The Nurses' Health Study 30 and EPIC-Prospect 32 explored haplotypes with MD. None were significantly associated with per-cent MD 29, 31 . P e r s P e c t i v e s Nature Reviews | Cancer Anti-proliferation, apoptosis Proliferation, anti-apoptosis although MD assessments were subjective and differed from the computer-assisted method used in the ePIC-Prospect study.
In a third study 52 , the computer-assisted method was used for all MD readings among mostly (~70%) postmenopausal women participating in the combined ePIC-Prospect and ePIC-Norfolk cohorts. In this study, the densities of 781 women who had never used PMH were compared at baseline and after 5 years across XbaI genotypes, to reflect the natural change in MD during this time period. In addition, MDs were compared across XbaI genotypes among 795 women who never used PMH at baseline but who subsequently initiated PMH use during the 5 years of follow-up, thereby reflecting the influence of PMH use during this period. The results suggested that the women who carried at least one x allele had significantly attenuated decreases in MD if they took PMH 52 . The PvuII polymorphism, which is in linkage disequilibrium with the XbaI polymorphism, was also studied in the two aforementioned investigations and showed similar results 47, 52 . Confirmation of these findings by independent investigators would suggest that PMH use interacts with the XbaI and PvuII polymorphisms to moderate the natural decrease in MD that is associated with the postmenopausal years, possibly to influence breast cancer risk, but this remains to be determined. The PvuII p allele and the XbaI x allele have each been associated with breast cancer [61] [62] [63] . . each copy of the val660leu allele was reported to increase breast cancer risk by a modest 8% (P = 0.05) 66 .
PGR PROGINS
IGFBP3 -202C>A. This polymorphism is located in the promoter region of the gene and may increase serum IGF binding protein 3 (IGFBP3) levels 67 . It has been investigated by five groups. examination of 215 healthy premenopausal women participating in a prospective study of breast cancer in the uK 48 and 741 healthy premenopausal women attending a mammography clinic in Quebec, Canada 54 showed no influence of the genotype on MD. A third study among 206 healthy premenopausal women attending an outpatient clinic in Toronto, Canada showed a significantly higher MD among women with two copies of the A allele 45 . each study used a computer-assisted method to assess MD. However, none of the studies defined the ethnic composition of their sample of women or adjusted for ethnicity. The potential for population stratification among a potentially multi-ethnic sample residing in Toronto 45 and the participants from the uK 48 and Quebec 54 warrants further exploration. In addition, postmenopausal women who had never used PMH or had used PMH in the past 45, 48 showed no appreciable difference in per-cent MD across genotypes of this polymorphism. Also, two additional studies, the Australian twin study of 307 postmenopausal women 50 and the Nurses' Health Study of 917 postmenopausal controls who participated Figure 1 | The insulin-like growth factor (iGf) axis. iGF1 has a role in regulating cellular growth, differentiation and apoptosis in normal breast and in mammary carcinogenesis and works in conjunction with growth hormone (GH), sex steroids and other hormones. GH-releasing hormone (GHrH) and its receptor (GHrHr) are both involved in the regulation of synthesis and release of GH by the pituitary gland. Although most iGF1 is synthesized in the liver in response to pituitary GH secretion, local production occurs in tissues including the breast. This autocrine and paracrine production of iGF1 within iGF1-responsive tissues is of major physiological importance and supports a role for iGF1 as a potent mitogen in the development of some cancers, including breast cancer 97 . iGF1 production is also influenced by oestradiol, which directly stimulates iGF1 production in oestrogen-responsive tissues through the association of oestrogen receptor α (esr1) with iGF1r 98 and indirectly stimulates iGF1 production in the liver through pituitary release of GH. in circulation, iGF1 binds to one of six different iGF binding proteins (the majority binds to iGFBP3). iGFBP3 is largely dependent on hepatic production and can prolong the half-life of iGF1 and prevent it from interacting with cell surface receptors (iGF1r). it is capable of modulating iGF1's biological response 97 by activating downstream signalling molecules including insulin receptor substrate 1 (irs1) and phosphoinositide 3-kinase (Pi3K) 98 . iGFBP3 production is negatively regulated by GH to limit apoptosis and anti-proliferative effects.
in a case-control study of breast cancer 30 , found no difference in MD across genotypes following adjustment for PMH use. In summary, the data suggest this polymorphism is not associated with MD regardless of menopausal status, although the C allele has been associated with lower circulating levels of IGFBP3 (ReF. 68) and marginally significant decreased breast cancer risk 66 .
IGF1 rs1520220 C>G and rs6220 A>G. The rs1520220 C>G polymorphism is located in intron 3 of IGF1 and rs6220 A>G is located in the 3′ untranslated region (uTR) 32 ). Only the Canadian study observed a significantly higher per-cent MD among women who carried two copies of the rs1520220 G allele 54 and both studies observed a marginally significantly higher per-cent MD with two copies of the rs6220 G allele 32, 54 . Both studies 32,54 also showed higher serum IGF1 with each polymorphism, although significance was attained with two copies of the rs6220 only 32 . Rs6220 A>G has also been associated with increased breast cancer risk 69 . A third study among healthy (204 premenopausal and 917 postmenopausal) women in the Nurses' Health Study observed significantly lower per-cent MD among those with both copies of the rs1520220 G allele, but no apparent difference was noted by menopausal status 30 . The evidence thus far does not support a consistent relation of rs1520220 C>G with MD or with breast cancer risk 70, 71 , although rs6220 A>G may be a potential candidate for premenopausal MD.
HSD3β1 Asn367Thr. One seemingly consistent finding among genes in the steroid hormone biosynthesis pathway (FIG. 2) is the lower level of MD among Caucasian carriers of the asparagine 367 to threonine (Asn367Thr) variant of hydroxysteroid dehydrogenase 3β1 (HSD3B1). This polymorphism has no known function. A cross-sectional study of 242 (~50% postmenopausal) Caucasian breast cancer patients with pre-diagnosis mammograms found a significantly lower per-cent MD among women with one or more copies of the Thr allele than in those with no copies 39 . This finding was confirmed in a study of 457 healthy Caucasian women (~67% postmenopausal) from 207 sisterhoods that also reported a significantly lower MD from one or more copies of the Thr allele 50 . Analyses restricted to 176 premenopausal women with two copies of the Thr allele displayed a non-significantly higher MD in the breast cancer study 39 , but a marginally significantly lower MD in the sisterhood study of 150 premenopausal women 50 . Potential reasons for the discrepancy could be variability from small sample sizes within subgroup analyses, the comparison of MD obtained retrospectively from women who were recruited as breast cancer cases with those of a selected group of twin pairs, and the slightly lower age among the breast cancer cases compared with the twin pairs, suggesting an enrichment of younger, higher-risk women in this study 39 . Although lower MD is seen for the Thr allele among Caucasian women after adjusting for menopausal status, the associations are inconsistent among premenopausal women, and not significant among postmenopausal women. The relevance of this polymorphism to MD, therefore, remains unclear. The association between the Asn367Thr variant and breast cancer risk has not been studied. CYP19A1 (TTTA) n . CYP19A1, also known as aromatase, contains a microsatellite repeat polymorphism that may alter the splice site during post-translational protein modification 72 ; however, no functional effect of the polymorphism on oestrogen biosynthesis is known 73 (FIG. 2) . 31, 41 . In the same studies, carriers of the 12-repeat allele had marginally significantly lower MD levels than women without this allele in one 31 but not in the other 41 investigation. Both were case-control studies of breast cancer and used the computer-assisted thresholding method of MD assessment among controls. Differences in polymorphism associations with MD may be from chance or from subtle ancestral differences among the Caucasian samples. Additional analyses of haplotypes that captured variation across the entirety of CYP19A1 with MD were not statistically significant 31 . Thus, the association of the CYP19A1 12-repeat allele with MD is inconclusive and does not appear to be associated with breast cancer 57, 74, 75 . CYP19A1 +27(TCT)+/-and +268T>C. CYP19A1 +27(TCT)+/-is an insertion/ deletion polymorphism in intron 4 and is in linkage disequilibrium with CYP19A1 (TTTA) n . CYP19A1 +268T>C resides in exon 10 of the 3′ uTR, but has no known function (FIG. 2) . Neither polymorphism was significantly associated with per-cent MD among 550 Caucasian women participating as controls in a case-control study of breast cancer in the united States (regardless of menopausal status or PMH use among postmenopausal women 31 ) or among 1,286 postmenopausal women of unreported ethnicity participating in a prospective cohort study in the uK who were past or never users of PMH 53 . A third study among 486 Caucasian controls in the united States also did not observe a significant
Glossary
Familial aggregation
A tendency for a trait to occur or cluster in multiple family members more often than would be expected by chance.
Genetic association studies
Tests whether a polymorphism in a candidate gene explains the inter-individual variation in a trait under study.
Haplotype blocks
Configurations of alleles within regions on the chromosome that tend to be inherited together (that is, are in high linkage disequilibrium). Little genetic variability is observed within this region among individuals in a population.
Linkage analysis
The process of determining the approximate chromosomal location of a gene associated with the trait being studied by looking for evidence of co-segregation with other marker genes whose locations are already known.
Linkage disequilibrium
Non-random association of alleles at two or more loci on chromosomes in a population, beyond that expected by chance.
Parent-offspring and twin studies
Investigates the proportion of variation in the trait under study that is explained by unmeasured additive genetic factors among respective relative pairs.
Segregation analysis
Tests hypotheses about whether the existence of major genes account for the observed pattern of familial aggregation of the trait and provides evidence for the mode of inheritance of the genes using pedigree data. statistical models compare Mendelian inheritance patterns of a trait to a model in which there are no restrictions on mode of inheritance or other model parameters.
Stroma
The supportive framework of a biological tissue with an extensive extracellular matrix that serves to support cells, separate tissues and regulate intercellular communication.
Tag single nucleotide polymorphisms (tagsNPs)
. A reduced set of single nucleotide polymorphisms that identify or 'tag' other sNPs with which it is in high linkage disequilibrium. association of the +268T>C polymorphism following adjustment for age and BMI and irrespective of menopausal status or use of PMH among postmenopausal women 41 . In the absence of additional data, these polymorphisms do not appear to be associated with MD or to be breast cancer risk factors 74, 75 .
AR CAG repeat polymorphism. Two studies investigated this polymorphism in the androgen receptor gene, AR (FIG. 2) . longer transcripts may produce a less active receptor 76, 77 . MD did not vary by number of AR CAG repeats among 538 (~73% postmenopausal) healthy Caucasian women with ≥22 repeats participating as controls in a study of breast cancer 41 or among 246 (~50% postmenopausal) Caucasian women with breast cancer with ≥21 repeats whose screening mammograms were retrieved within the 5 years preceding their cancer diagnosis 40 . The control study 41 did not observe an effect on per-cent MD from PMH use, although the women with breast cancer 40 with the longer less-active AR allele had higher MD if they also took a combined formulation of oestrogen plus progesterone PMH. The associations with MD may reflect a large number of comparisons in the data of relatively small numbers of women 40 . Moreover, the AR polymorphism is inconsistently associated with breast cancer risk 78, 79 . Tumour suppressor genes. Over 750 proteintruncating mutations exist in BRCA1 and BRCA2 (see ReF. 80 and Breast Cancer Information Core uRl in Further information). Findings from early studies were mixed [33] [34] [35] [36] and relied on varied methods of qualitative assessments of MD in addition to small sample sizes of 9-34 mutation carriers (TABLe 1) . A recent well-designed study using the computer-assisted thresholding assessment found no difference in MD between 206 mutation carriers and 136 non-carriers after adjustment for age at mammography and BMI 49 (see Supplementary information S1 (table)). Although strong risk factors for heritable breast cancer, these mutations are not associated with MD. C, e, J, K, v and Z (no observed effect from F-i, O, Q, r and AA-ee) 54 *Covariates: A, age; B, race or ethnicity; C, body mass index; D, menopausal status/postmenopausal hormone (PMH) use; e, parity; F, age at first birth; G, age at menarche; H, family history of breast cancer; i, alcohol intake; J, waist circumference or waist-to-hip ratio; K, smoking; L, years since menopause; M, change in body mass index during study period; N, density at baseline; O, past use of PMH; P, study arm/population; Q, oral contraceptive use; r, physical activity; s, coffee intake; T, time since blood draw; U, year of breast cancer diagnosis; v, age at mammogram; w, case-control status; X, history of benign breast disease; Y, geographical region of residence; Z, previous breast biopsies; AA, height; BB, total energy intake; CC, lactation; DD, education; ee, season of recruitment. AiB, amplified in breast; AKr, aldo-keto reductase; Ar, androgen receptor; Bi-rADs, Breast imaging-reporting and Data systems; COMT, catechol-O-methyltransferase; CYP, cytochrome P450; DZ, dizygotic; esr, oestrogen receptor; FGFr, fibroblast growth factor receptor; GH, growth hormone; GHrHr, GH-releasing hormone receptor; HsD, hydroxysteroid dehydrogenase; iGF, insulin-like growth factor; iGFBP, iGF binding protein; irs, insulin receptor substrate; LsP, lymphocyte-specific protein; MD, mammographic density; MZ, monozygotic; PGr, progesterone receptor; PiK3BC, phosphoinositide 3-kinase, catalytic, beta polypeptide; sHBG, sex hormone binding globulin; UGT, UDP-glucuronosyltransferase; UsC, University of southern California; UT, University of Toronto, X-sectional, cross-sectional. 
CYP1A2 -154A>C (CYP1A1*1F).
This polymorphism may induce the enzyme, CYP1A2, to lower bioactive oestrogen concentrations 81 and, hypothetically, MD. A marginally significantly lower MD was observed overall among 268 premenopausal and 60 postmenopausal women screened in a mammography clinic, and particularly among premenopausal women 46 , whereas a statistically significantly higher MD was reported among control subjects from a case-control study of breast cancer in 97 premenopausal and 153 postmenopausal women 38 . Interestingly, both studies sampled from among female residents in Hawaii, uSA. The mammography clinic study 46 comprised healthy women with an entry (baseline) mammogram, whereas the casecontrol study 38 incorporated healthy women participating in two case-control studies nested within the Multiethnic Cohort Study who had an average of 2.5 mammograms in order to reduce intra-individual variability in MD measurements. Given similarities in computerized mammographic assessments and adjustment with similar covariates, the findings from the latter study 38 may be more reliable owing to increased precision of the measure. With only two studies, the influence of the polymorphism with MD is inconclusive, as is its association with breast cancer in the Shanghai Breast Cancer Study 82 , although decreased risk has been observed among predominantly postmenopausal women in the Multiethnic Cohort Study 59 . Figure 2 | pathways of steroid hormone synthesis, metabolism and sensitivity of tissues. a | steroid hormone biosynthesis. Cytochrome P450 17A1 (CYP17A1) catalyses the conversion of pregnenolone and progesterone to the hormones dehydroepidandrosterone (DHeA) and androstenedione, respectively, which are further metabolized to oestrone (e1) and 17β-oestradiol (e2) by CYP19A1 (aromatase). Androgen conversion to oestrogen in adipose tissue by CYP19A1 is an important source of bioactive endogenous oestrogens among postmenopausal women. Hydroxysteroid dehydrogenase 3β1 (HsD3β1) catalyses the interconversion of pregnenolone and progesterone and of DHeA and androstenedione, whereas HsD17β1 catalyses the interconversions of androstenedione and testosterone and of e1 and e2. Testosterone and e2 bind to the serum sex hormone binding globulin (sHBG), which regulates the bioavailability of these hormones in target cells. b | Oestrogen catabolism. The CYP1 family of enzymes are phase i enzymes that function in the oxidative metabolic activation and deactivation of compounds including several steroid hormones. e1 and e2 undergo 2-hydroxylation by the CYP1A1 and CYP1A2 enzymes and 4-hydroxylation by CYP1B1. Catecholoestrogens are deactivated by catechol-O-methyltransferase (COMT). UDP-glucuronosyltransferase 1A1 (UGT1A1) is a detoxifying enzyme that converts endogenous substrates including e1 or e2 and their metabolites to inactive hydrophilic glucuronides. c | Progesterone catabolism. Aldo-keto reductase family 1 member C4 (AKr1C4) catalyses the conversion of progesterone and androstenedione to their corresponding alcohols. d | Gene transcription. Progesterone, testosterone and e2 bind to their respective nuclear receptor proteins, progesterone receptor (Pr), androgen receptor (Ar) and oestrogen receptor α (esr1), and activate genes with corresponding responsive elements. The steroid receptor co-activator protein, amplified in breast 1 (AiB1) interacts with esr1 in a ligand-dependent manner to increase oestrogen-dependent transcription.
CYP1A1 Ile462Val and CYP1B1
Val432Leu. Higher CYP1A1 expression 81 or activity 83 and CYP1B1 activity 84, 85 may lower bioactive oestrogen concentrations (FIG. 2) . Neither polymorphism was associated with MD among predominantly premenopausal 46 or predominantly postmenopausal 41 healthy women. Also, CYP1B1 val432leu was not associated with MD among 1,260 cohort members who were past or never users of PMH 53 . MD among 140 current users of PMH with both copies of the CYP1B1 leu allele, however, was lower than carriers of both val alleles, although this was of borderline significance only 41 . This relation among current users was not evaluated in the other studies and requires confirmation. Neither polymorphism is strongly associated with breast cancer 57, 59, 83, 86 .
Summary. The hypothesis-dependent approach focusing on candidate genes that might influence breast cancer has produced mostly conflicting results regardless of whether the polymorphisms have known functional effects (TABLe 2) . Indeed, the accumulated evidence indicates that the COMT val158Met and IGF1 rs6220 3′ uTR polymorphisms (or variants in strong linkage disequilibrium with these polymorphisms) influence per-cent MD in premenopausal women, and the ESR1 intronic XbaI and PvuII variants may lead to higher per-cent MD among women taking PMH. The remaining studies are inconclusive, mostly owing to too few independent investigations or to between-study heterogeneity in sample characteristics.
Linkage analysis A major limitation of candidate gene studies is the low prior probability that an association is true 87 . Selecting candidate genes in a region with prior evidence of genetic linkage directly addresses this weakness. Because the regions identified by linkage analysis are hypothesis-independent, they can identify a gene (or genes) that is not anticipated. In multifactorial complex traits such as MD this is particularly important.
Two linkage analyses of MD have been conducted. Both used a large breast cancer family study as the sampling frame. The first was a small sibling pair study of 71 sisterhoods in 22 families and used 147 microsatellite markers placed across the autosomes at a spacing of 30 centiMorgans (cM). The results indicated a possible linkage to chromosome 6 (ReF. 88 ). The second larger study included 889 members of 89 multigenerational families and 403 markers spaced an average of 9 cM apart 89 . The strongest evidence for linkage was identified on chromosome 5p with a maximum log odds for linkage (or lOD) of 2.9. Finer mapping of this region with a dense set of markers strengthened the evidence for linkage (lOD = 4.2). The 1-lOD region, which contains 45 genes, has not been previously implicated in breast cancer and is currently being pursued. Further, although this locus was not linked to BMI, it was only apparent after adjustment for BMI, and could explain up to 22% of the total variability in MD among women. Two other suggestive regions for linkage were also identified on chromosome 12, one containing the IGF1 gene. Thus linkage analysis can result in identification of novel genes that might influence both MD and breast cancer risk.
Genome-wide association studies Genome-wide association studies (GWASs) use a large number of polymorphisms positioned across the genome. Poly mor phisms are not confined to coding or regulatory regions and the function of the majority of these polymorphisms is unknown. No GWAS has been reported for MD, but six polymorphisms identified from three GWASs of breast cancer [90] [91] [92] have been evaluated by one investigative team in relation to MD (see Supplementary information S1 (table) ). In this study of 516 Caucasian breast cancer cases, lee et al. 51 observed no association of these variants with MD using the mammogram of the contralateral (non-cancerous) breast, although a positive association with MD of rs3817198 T>C within lymphocyte-specific protein 1 (LSP1) on chromosome 11p was seen specifically in women with tumours positive for both 37, 41 (CAG) n repeat 40, 41 3′ UTr G>A 30, 32 , -178C>G No consistent association in >1 study (for example, studies that vary in significant findings or significant studies that vary in direction of effect). AiB, amplified in breast; AKr, aldo-keto reductase; Ar, androgen receptor; COMT, catechol-O-methyltransferase; CYP, cytochrome P450; esr, oestrogen receptor; GH, growth hormone; HsD, hydroxysteroid dehydrogenase; iGF, insulin-like growth factor; iGFBP, iGF binding protein; PGr, progesterone receptor; PiK3BC, phosphoinositide 3-kinase, catalytic, beta polypeptide; UGT, UDP-glucuronosyltransferase.
oestrogen receptor eSR1 and PR. One of the functions of lSP1 is to regulate adhesion to fibrinogen matrix proteins, which may have implications for MD.
Summary and future directions
There is strong evidence for a genetic component to MD. Both hypothesisdependent and hypothesis-free approaches have provided clues to relevant genes and loci. Candidate gene approaches yielded replicated associations between COMT val158Met and IGF1 rs6220 A>G and premenopausal MD, and ESR1 (XbaI and PvuII) polymorphisms and postmenopausal MD, which possibly translate to breast cancer risk. However, many polymorphisms have only been examined in a few studies, limiting the conclusions that can be drawn (TABLe 2) . Technological advances make genomewide scans feasible and may reveal novel candidate genes, and haplotype block or tag single-nucleotide polymorphism approaches are advantageous in studying all common variation within a gene. linkage analyses identified a candidate region on chromosome 5p encompassing 45 genes that are also under consideration for their influence on MD.
Future investigations should incorporate well-characterized study populations including specification of age, race and ethnicity; quantify MD, and its changes in the most objective manner possible; stratify subjects by design (rather than post-hoc) by menopause and specific type of hormone regimen with MDs reflecting the timing of PMH exposure; and consider assessment of earlier periods in life when MD changes are most dramatic and the inter-individual variation is greatest. Several protocols reviewed in this Perspective drive these recommendations and are strong studies for future comparisons and synthesis 32, 48, 52 . Also, the reviewed studies underscore the importance of measuring and accounting for non-heritable factors to allow better detection of genetic influences on MD. Several of the polymorphisms examined thus far have inconclusive functional significance, requiring research to understand tissue response to genetic polymorphisms that alter local biosynthesis, metabolism or catabolism of hormones or growth factors. ultimately, identification of genetic risk factors for early markers of disease may permit better risk prediction and targeted early preventive or therapeutic strategies for breast cancer.
